These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 15464063

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.
    J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
    Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ.
    J Pharmacol Exp Ther; 2011 Jun; 337(3):786-96. PubMed ID: 21411496
    [Abstract] [Full Text] [Related]

  • 7. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Jun; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 8. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.
    J Med Chem; 2004 Apr 22; 47(9):2375-88. PubMed ID: 15084136
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
    Gunnet JW, Wines P, Xiang M, Rybczynski P, Andrade-Gordon P, de Garavilla L, Parry TJ, Cheung WM, Minor L, Demarest KT, Maryanoff BE, Damiano BP.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):333-42. PubMed ID: 18599033
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Identification of novel selective V2 receptor non-peptide agonists.
    Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F.
    Biochem Pharmacol; 2008 Oct 30; 76(9):1134-41. PubMed ID: 18761325
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.
    Pena A, Murat B, Trueba M, Ventura MA, Bertrand G, Cheng LL, Stoev S, Szeto HH, Wo N, Brossard G, Serradeil-Le Gal C, Manning M, Guillon G.
    Endocrinology; 2007 Sep 30; 148(9):4136-46. PubMed ID: 17495006
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance.
    Nakamura K, Aoyagi T, Hiroyama M, Kusakawa S, Mizutani R, Sanbe A, Yamauchi J, Kamohara M, Momose K, Tanoue A.
    Eur J Pharmacol; 2009 Jun 24; 613(1-3):182-8. PubMed ID: 19375419
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression of vasopressin receptors in ACTH-independent macronodular bilateral adrenal hyperplasia causing Cushing's syndrome: molecular, immunohistochemical and pharmacological correlates.
    Louiset E, Contesse V, Groussin L, Cartier D, Duparc C, Perraudin V, Bertherat J, Lefebvre H.
    J Endocrinol; 2008 Jan 24; 196(1):1-9. PubMed ID: 18180312
    [Abstract] [Full Text] [Related]

  • 19. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 Jan 24; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 20. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology.
    Chini B, Manning M, Guillon G.
    Prog Brain Res; 2008 Jan 24; 170():513-7. PubMed ID: 18655904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.